

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6921310

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS AG	09/15/2021
RECEIVING PARTY DATA	
Name:	NOVARTIS PHARMACEUTICALS CORPORATION
Street Address:	ONE HEALTH PLAZA
City:	EAST HANOVER
State/Country:	NEW JERSEY
Postal Code:	07936
PROPERTY NUMBERS Total: 5	
Property Type	Number
Patent Number:	9517226
Patent Number:	9937143
Application Number:	15912701
Patent Number:	11058667
Application Number:	17371585
CORRESPONDENCE DATA	
Fax Number:	(617)871-3392
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617)871-3544
Email:	pip_inbox.phchbs@novartis.com, diana.mabry@novartis.com
Correspondent Name:	DIANA MABRY
Address Line 1:	700 MAIN STREET
Address Line 2:	4TH FLOOR
Address Line 4:	CAMBRIDGE, MASSACHUSETTS 02139
ATTORNEY DOCKET NUMBER:	PAT055244
NAME OF SUBMITTER:	DIANA MABRY
SIGNATURE:	/Diana Mabry/
DATE SIGNED:	09/17/2021
Total Attachments: 8	

source=Assignment NAG to NPC#page1.tif
source=Assignment NAG to NPC#page2.tif
source=Assignment NAG to NPC#page3.tif
source=Assignment NAG to NPC#page4.tif
source=Assignment NAG to NPC#page5.tif
source=Assignment NAG to NPC#page6.tif
source=Assignment NAG to NPC#page7.tif
source=Assignment NAG to NPC#page8.tif

ASSIGNMENT

This PATENT ASSIGNMENT ("Assignment") is entered into by and between **NOVARTIS AG**, a corporation organized under the laws of Switzerland having a place of business at Lichtstrasse 35, 4056 Basel, Switzerland ("Assignor"), and **NOVARTIS PHARMACEUTICALS CORPORATION**, a corporation organized under the laws of Delaware having a place of business at One Health Plaza, East Hanover, New Jersey 07936 ("Assignee"). Assignor and Assignee are collectively referred to herein as the "Parties."

The Parties agree as follows:


For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **NOVARTIS AG** does hereby sell, assign, and transfer to **NOVARTIS PHARMACEUTICALS CORPORATION**, and its successors, assigns, and legal representatives (hereinafter referred to collectively as the "Assignee"), all of its right, title, and interest in and to

- (i) the patents and applications listed in Schedule A hereto;
- (ii) all continuations, continuations-in-part, divisionals, and reissues of any United States patent application(s) in (i), including for example further continuations, continuations-in-part, and divisionals, such as, but not limited to, continuations of continuations and continuations of divisionals; and
- (iii) all patent term extensions and adjustments relying on or connected to any of (i) or (ii) (the foregoing (i), (ii), and (iii) comprising the "Assigned Patents").


The Parties hereby request and authorize the authority at the relevant national patent office to record Assignee as the recorded holder of title, legal owner, registered owner, assignee, and/or applicant, as the case may be, of the Assigned Patents.

Executed this 15th day of Sept, 2021.

NOVARTIS AG

BY 
Printed Name:
Authorized Signatory **Robert Stanley**

NOVARTIS AG

BY 
Printed Name:
Authorized Signatory **Isabelle Schubert Santana**

Executed this _____ day of _____, 20_____ .

NOVARTIS PHARMACEUTICALS CORPORATION

BY _____

Printed Name:

Authorized Signatory

SCHEDULE A

Docket Number	Country	Application Number	Filing Date	Grant No.
PAT055244-US-PCT	US	14/422,855	20 February 2015	9,517,226
PAT055244-US-CNT	US	15/345,941	8 November 2016	9,937,143
PAT055244-US-CNT02	US	15/912,701	6 March 2018	
PAT056901-US-PCT	US	15/572,399	7 November 2017	11,058,667
PAT056901-US-CNT	US	17/371,585	9 July 2021	

ASSIGNMENT

This PATENT ASSIGNMENT ("Assignment") is entered into by and between **NOVARTIS AG**, a corporation organized under the laws of Switzerland having a place of business at Lichtstrasse 35, 4056 Basel, Switzerland ("Assignor"), and **NOVARTIS PHARMACEUTICALS CORPORATION**, a corporation organized under the laws of Delaware having a place of business at One Health Plaza, East Hanover, New Jersey 07936 ("Assignee"). Assignor and Assignee are collectively referred to herein as the "Parties."

The Parties agree as follows:

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **NOVARTIS AG** does hereby sell, assign, and transfer to **NOVARTIS PHARMACEUTICALS CORPORATION**, and its successors, assigns, and legal representatives (hereinafter referred to collectively as the "Assignee"), all of its right, title, and interest in and to

- (i) the patents and applications listed in Schedule A hereto;
- (ii) all continuations, continuations-in-part, divisionals, and reissues of any United States patent application(s) in (i), including for example further continuations, continuations-in-part, and divisionals, such as, but not limited to, continuations of continuations and continuations of divisionals; and
- (iii) all patent term extensions and adjustments relying on or connected to any of (i) or (ii) (the foregoing (i), (ii), and (iii) comprising the "Assigned Patents").

The Parties hereby request and authorize the authority at the relevant national patent office to record Assignee as the recorded holder of title, legal owner, registered owner, assignee, and/or applicant, as the case may be, of the Assigned Patents.

Executed this _____ day of _____, 20_____ .

NOVARTIS AG


BY _____
Printed Name:
Authorized Signatory

NOVARTIS AG

BY _____
Printed Name:
Authorized Signatory

Executed this 15th day of September 20 21.

NOVARTIS PHARMACEUTICALS CORPORATION

BY: 

Printed Name:

Authorized Signatory Robert M Gleason
Secretary to the Board

SCHEDULE A

Docket Number	Country	Application Number	Filing Date	Grant No.
PAT055244-US-PCT	US	14/422,855	20 February 2015	9,517,226
PAT055244-US-CNT	US	15/345,941	8 November 2016	9,937,143
PAT055244-US-CNT02	US	15/912,701	6 March 2018	
PAT056901-US-PCT	US	15/572,399	7 November 2017	11,058,667
PAT056901-US-CNT	US	17/371,585	9 July 2021	